{"id":"https://openalex.org/W3029624192","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.3640","title":"Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.","display_name":"Phase I dose-finding study of oral ERK1/2 inhibitor LTT462 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.","publication_year":2020,"publication_date":"2020-05-20","ids":{"openalex":"https://openalex.org/W3029624192","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.3640","mag":"3029624192"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2020.38.15_suppl.3640","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.3640","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.3640","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5071800834","display_name":"Filip Jank\u00fa","orcid":"https://orcid.org/0000-0002-8123-4065","observed_orcids":["https://orcid.org/0000-0002-8123-4065"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Filip Janku","raw_affiliation_strings":["Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX;","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030657436","display_name":"Elena \u00c9lez","orcid":"https://orcid.org/0000-0002-4653-6324","observed_orcids":["https://orcid.org/0000-0002-4653-6324","https://orcid.org/0000-0002-9178-0246"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Elena Elez","raw_affiliation_strings":["Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain;","institution_ids":["https://openalex.org/I4210127641"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064203357","display_name":"Gopa Iyer","orcid":"https://orcid.org/0000-0002-5093-6099","observed_orcids":["https://orcid.org/0000-0002-5093-6099"]},"institutions":[{"id":"https://openalex.org/I1334819555","display_name":"Memorial Sloan Kettering Cancer Center","ror":"https://ror.org/02yrq0923","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334819555"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gopa Iyer","raw_affiliation_strings":["Memorial Sloan Kettering Cancer Center, New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Memorial Sloan Kettering Cancer Center, New York, NY;","institution_ids":["https://openalex.org/I1334819555"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030587345","display_name":"Noboru Yamamoto","orcid":"https://orcid.org/0000-0002-0787-2851","observed_orcids":["https://orcid.org/0000-0002-0787-2851"]},"institutions":[{"id":"https://openalex.org/I4405285273","display_name":"National Cancer Center Hospital","ror":"https://ror.org/053hhpd64","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210087348","https://openalex.org/I4405285273"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Noboru Yamamoto","raw_affiliation_strings":["Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan;","institution_ids":["https://openalex.org/I4405285273"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109602065","display_name":"Daniel Shao-Weng Tan","orcid":"https://orcid.org/0009-0005-4021-2176","observed_orcids":["https://orcid.org/0009-0005-4021-2176"]},"institutions":[{"id":"https://openalex.org/I4210137145","display_name":"National Cancer Centre Singapore","ror":"https://ror.org/03bqk3e80","country_code":"SG","type":"healthcare","lineage":["https://openalex.org/I4210137145"]}],"countries":["SG"],"is_corresponding":false,"raw_author_name":"Daniel Shao-Weng Tan","raw_affiliation_strings":["National Cancer Centre, Singapore, Singapore;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Cancer Centre, Singapore, Singapore;","institution_ids":["https://openalex.org/I4210137145"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048622832","display_name":"Anastasios Stathis","orcid":"https://orcid.org/0000-0002-2859-7529","observed_orcids":["https://orcid.org/0000-0002-2859-7529"]},"institutions":[{"id":"https://openalex.org/I4404532900","display_name":"Istituto Oncologico della Svizzera Italiana","ror":"https://ror.org/04tty5b50","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210095212","https://openalex.org/I4404532900"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Anastasios Stathis","raw_affiliation_strings":["Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oncology Institute of Southern Switzerland, Bellinzona, Switzerland;","institution_ids":["https://openalex.org/I4404532900"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084841849","display_name":"Uz M. Stammberger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Uz M. Stammberger","raw_affiliation_strings":["Novartis Institutes for BioMedical Research, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Institutes for BioMedical Research, Basel, Switzerland;","institution_ids":["https://openalex.org/I4400600974"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Helen Evans","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Helen Evans","raw_affiliation_strings":["Novartis Institutes for BioMedical Research, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Institutes for BioMedical Research, Basel, Switzerland;","institution_ids":["https://openalex.org/I4400600974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008906778","display_name":"Abdelkader Seroutou","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Abdelkader Seroutou","raw_affiliation_strings":["Novartis Institutes for BioMedical Research, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Institutes for BioMedical Research, Basel, Switzerland;","institution_ids":["https://openalex.org/I4400600974"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101143912","display_name":"Anna Mais","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4400600974","display_name":"Novartis Institutes for BioMedical Research","ror":"https://ror.org/053gv2m95","country_code":"CH","type":"funder","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4400600974"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Anna Mais","raw_affiliation_strings":["Novartis Institutes for BioMedical Research, Basel, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Institutes for BioMedical Research, Basel, Switzerland;","institution_ids":["https://openalex.org/I4400600974"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5036507802","display_name":"Martin Sch\u00fcler","orcid":"https://orcid.org/0000-0002-2166-3394","observed_orcids":["https://orcid.org/0000-0002-2166-3394"]},"institutions":[{"id":"https://openalex.org/I4210119759","display_name":"Essen University Hospital","ror":"https://ror.org/02na8dn90","country_code":"DE","type":"funder","lineage":["https://openalex.org/I4210119759"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Martin H. Schuler","raw_affiliation_strings":["West German Cancer Center, Department of Medical Oncology, University Hospital Essen, Essen, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"West German Cancer Center, Department of Medical Oncology, University Hospital Essen, Essen, Germany;","institution_ids":["https://openalex.org/I4210119759"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":26,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"38","issue":"15_suppl","first_page":"3640","last_page":"3640"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9897000193595886,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0024999999441206455,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.002099999925121665,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erk1-2-inhibitor","display_name":"ERK1/2 inhibitor","score":0.9909999966621399},{"id":"https://openalex.org/keywords/mapk-pathway-alterations","display_name":"MAPK pathway alterations","score":0.9769999980926514},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.9879999756813049},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.722000002861023},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.9779999852180481},{"id":"https://openalex.org/keywords/retinopathy","display_name":"retinopathy","score":0.8690000176429749},{"id":"https://openalex.org/keywords/chorioretinopathy","display_name":"chorioretinopathy","score":0.9359999895095825},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.7459999918937683},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8820000290870667},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9150000214576721},{"id":"https://openalex.org/keywords/oral-small-molecule-inhibitor","display_name":"oral small-molecule inhibitor","score":0.4560000002384186},{"id":"https://openalex.org/keywords/first-in-human-safety","display_name":"first-in-human safety","score":0.5329999923706055},{"id":"https://openalex.org/keywords/braf-v600e-mutation","display_name":"BRAF V600E mutation","score":0.5899999737739563},{"id":"https://openalex.org/keywords/kras-g12c","display_name":"KRAS G12C","score":0.5709999799728394},{"id":"https://openalex.org/keywords/braf-v600d","display_name":"BRAF V600D","score":0.6779999732971191}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8928324580192566},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.6611107587814331},{"id":"https://openalex.org/C2780580376","wikidata":"https://www.wikidata.org/wiki/Q186889","display_name":"Nausea","level":2,"score":0.6557875871658325},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6471183896064758},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5999965667724609},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5751972794532776},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5564673542976379},{"id":"https://openalex.org/C2779984678","wikidata":"https://www.wikidata.org/wiki/Q2145898","display_name":"Response Evaluation Criteria in Solid Tumors","level":4,"score":0.5185126066207886},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4795805513858795},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4467829763889313},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.43722009658813477},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.4357481598854065},{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.4149574339389801},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.3471028208732605},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.28367307782173157},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.26645755767822266},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2020.38.15_suppl.3640","doi":"https://doi.org/10.1200/jco.2020.38.15_suppl.3640","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2020.38.15_suppl.3640","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[{"id":"https://openalex.org/F4320307778","display_name":"Novartis","ror":"https://ror.org/02f9zrr09"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4399327768","https://openalex.org/W2673262484","https://openalex.org/W2595398870","https://openalex.org/W2591414794","https://openalex.org/W4399327928","https://openalex.org/W2788978455","https://openalex.org/W2774483419","https://openalex.org/W2084184238","https://openalex.org/W4286293799","https://openalex.org/W2590829569"],"abstract_inverted_index":{"3640":[0],"Background:":[1],"LTT462":[2,37,89,264,313,331,347,362,385],"is":[3,83,363,383],"an":[4],"investigational":[5],"small":[6],"molecule":[7],"inhibitor":[8],"of":[9,36,51,138,227,252,263,305,342],"ERK1/2,":[10],"which":[11],"has":[12],"demonstrated":[13],"preclinical":[14],"activity":[15,368],"in":[16,38,154,171,250,293,303,357,386,393],"multiple":[17],"MAPK":[18,43,69],"activated":[19],"cancer":[20,169],"cells":[21],"and":[22,34,59,130,135,183,239,269,281,319,350,395],"xenograft":[23],"models.":[24],"This":[25],"first-in-human":[26],"study":[27,382],"was":[28,90,256,265,291,311,335,369,378],"designed":[29],"to":[30,110,195,355],"evaluate":[31],"the":[32,112,155,172,192,389],"safety":[33],"tolerability":[35],"advanced":[39,63],"solid":[40,64],"tumors":[41,65],"harboring":[42,66],"pathway":[44,70],"alterations":[45],"(NCT02711345).":[46],"Methods:":[47],"The":[48],"dose-escalation":[49],"part":[50],"this":[52,345],"Phase":[53],"I,":[54],"open-label":[55],"study,":[56],"enrolled":[57,153],"adult":[58],"adolescent":[60],"pts":[61,142,158,190,202,206,214,217,275,283,359],"with":[62,72,127,296,298,371,388],"\u22651":[67],"documented":[68],"alteration":[71],"progressive":[73],"disease":[74,279],"(PD)":[75],"despite":[76],"standard":[77,86],"therapy,":[78],"or":[79,98,105],"for":[80,168,225],"whom":[81],"there":[82],"no":[84],"effective":[85],"treatment.":[87],"Oral":[88],"given":[91],"once":[92],"daily":[93,100],"(QD)":[94],"at":[95,102,322,330,344],"45\u2013600":[96],"mg":[97,104,267,271,327,333],"twice":[99],"(BID)":[101],"150":[103,270],"200":[106],"mg.":[107],"Objectives":[108],"were":[109,152,170,223,248],"determine":[111],"maximum":[113],"tolerated":[114],"dose":[115],"(MTD)":[116],"using":[117],"a":[118,294],"Bayesian":[119],"hierarchical":[120],"logistic":[121],"regression":[122],"model":[123],"guided":[124],"by":[125],"escalation":[126],"overdose":[128],"control,":[129],"characterize":[131],"safety,":[132],"pharmacokinetics,":[133],"pharmacodynamics,":[134],"preliminary":[136],"efficacy":[137],"LTT462.":[139],"Results:":[140],"Sixty-five":[141],"(median":[143],"age":[144],"60":[145],"years)":[146],"including":[147],"1":[148],"pt":[149,295],"aged":[150],"15":[151],"dose-escalation;":[156],"most":[157,229,254,358],"(22%)":[159],"had":[160,277,285],"3":[161,209],"prior":[162],"therapies.":[163],"Most":[164],"common":[165,255],"primary":[166],"sites":[167],"colon":[173],"(n":[174,179,185,197,235,241,258],"=":[175,180,186,198,236,242,259],"21;":[176],"32%),":[177],"ovary":[178],"9;":[181],"14%),":[182],"pancreas":[184],"7;":[187],"11%).":[188],"All":[189],"discontinued,":[191],"majority":[193],"due":[194],"PD":[196],"44;":[199],"68%).":[200],"Eleven":[201],"experienced":[203,207],"DLTs;":[204],"6":[205],"Grade":[208,245],"eye":[210],"disorder":[211],"DLTs":[212],"(4":[213],"retinopathy,":[215],"2":[216],"chorioretinopathy).":[218],"Treatment-related":[219],"adverse":[220],"events":[221],"(TRAEs)":[222],"reported":[224,249,292,370],"89%":[226],"pts,":[228],"commonly":[230],"(":[231],">":[232],"30%)":[233],"diarrhea":[234],"25;":[237],"38%)":[238],"nausea":[240],"22;":[243],"34%).":[244],"3/4":[246],"TRAEs":[247],"29%":[251],"pts;":[253],"retinopathy":[257],"4;":[260],"6%).":[261],"MTD":[262],"400":[266],"QD":[268,334],"BID.":[272],"Overall,":[273],"8":[274],"(12%)":[276],"stable":[278],"(SD)":[280],"35":[282],"(54%)":[284],"PD.":[286],"An":[287,380],"unconfirmed":[288],"partial":[289],"response":[290,377],"cholangiocarcinoma":[297],"BRAF":[299],"mutation;":[300],"best":[301,375],"change":[302],"sum":[304],"target":[306],"lesions":[307],"per":[308],"RECIST":[309],"1.1":[310],"-33.9%.":[312],"increased":[314],"plasma":[315],"peak":[316],"drug":[317,320],"concentration":[318],"exposure":[321],"increasing":[323],"doses":[324],"between":[325],"45\u2013450":[326],"QD.":[328],"Exposure":[329],"600":[332],"lower":[336],"than":[337],"anticipated,":[338],"indicating":[339],"potential":[340],"saturation":[341],"absorption":[343],"dose.":[346],"inhibited":[348],"ERK1/2":[349],"reduced":[351],"DUSP6":[352],"expression":[353],"relative":[354],"baseline":[356],"evaluated.":[360],"Conclusions:":[361],"well":[364],"tolerated.":[365],"Limited":[366],"clinical":[367],"single":[372],"agent":[373],"LTT462;":[374],"overall":[376],"SD.":[379],"ongoing":[381],"investigating":[384],"combination":[387],"RAF":[390],"inhibitor,":[391],"LXH254,":[392],"NSCLC":[394],"melanoma.":[396],"Clinical":[397],"trial":[398],"information:":[399],"NCT02711345":[400],".":[401]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":11},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":2}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2020-06-05T00:00:00"}